Related Experiment Videos

Naturally processed HLA class I bound peptides from c-myc-transfected cells reveal allele-specific motifs

P E Harris1, A Colovai, Z Liu

  • 1Division of Immunogenetics, College of Physicians and Surgeons of Columbia University, New York, NY 10032.

Insights

Researchers analyzed peptides bound to HLA molecules from c-myc transfected cells, identifying three distinct structural motifs. One peptide, HEETPPTTS, matched a region of the c-myc protein, suggesting potential immune targets.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Peptides naturally processed and presented by Major Histocompatibility Complex (MHC) class I molecules are crucial for T-cell recognition.
  • The c-myc oncogene is frequently dysregulated in various cancers, making its protein products potential targets for immunotherapy.

Purpose of the Study:

  • To characterize naturally processed peptides bound to human leukocyte antigen (HLA)-A2, HLA-A68, and HLA-B40 molecules.
  • To identify potential tumor-associated antigens derived from the c-myc protein.

Main Methods:

  • Isolation and sequence analysis of peptides naturally bound to HLA-A2, HLA-A68, and HLA-B40 molecules from c-myc transfected lymphoblastoid B cell lines.
  • Grouping of peptide sequences based on structural motifs and comparison with known peptide-binding specificities.

Main Results:

  • Forty-three peptide sequences were identified and categorized into three distinct structural motifs.
  • One motif corresponded to previously reported HLA-A2 and HLA-A68 binding patterns.
  • A novel motif associated with HLA-B40 was identified, characterized by specific amino acid residues in the peptide's binding groove.
  • A peptide, HEETPPTTS, within the HLA-B40 motif was found to be 100% homologous to residues 243-251 of the c-myc protein.

Conclusions:

  • Naturally processed peptides bound to HLA-A2, HLA-A68, and HLA-B40 molecules exhibit distinct structural motifs.
  • The identification of a c-myc-derived peptide bound to HLA-B40 suggests its potential as a target for cancer immunotherapy.

Related Concept Videos